Fibrostenosis Focused Therapeutics - RFP
Supports translational research and development of innovative, non-surgical therapies for fibrosis in IBD, with emphasis on clinical and multidisciplinary approaches.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (Letter of Intent) | August 14, 2026 (Full Proposal)
Funding Amounts: Up to $450,000 per project for one year; renewal possible for additional $450,000 if milestones are achieved.
Summary: Supports development of innovative, non-surgical therapies for fibrotic complications in IBD, emphasizing translational and multidisciplinary approaches.
Key Information: Preproposal required before LOI; only invited LOIs may submit full proposals.
Description
This funding opportunity aims to accelerate the development of novel, non-surgical therapeutic products targeting fibrotic complications (fibrostenosis) in inflammatory bowel disease (IBD), specifically Crohn’s disease and ulcerative colitis. The Crohn’s & Colitis Foundation is seeking proposals from companies and academic groups (associated with drug discovery centers) for research and development projects rooted in clinical observations or published human IBD evidence. Projects of particular interest include those evaluating the therapeutic potential of modulating specific fibrotic pathways and employing multidisciplinary, translational approaches. The ultimate goal is to address the significant unmet need for effective, non-surgical treatments for fibrosis-related complications in IBD patients.
